Phospho-MYC (Ser62) Antibody

What is the biological significance of c-Myc phosphorylation at Serine-62?

Phosphorylation of c-Myc at Serine-62 is a critical post-translational modification that stabilizes the c-Myc protein and enhances its transcriptional activity. This modification increases c-Myc's DNA binding capacity, particularly to E-box sequences, which promotes the expression of growth-related genes. Studies show that cells with increased phosphorylation at Ser-62 exhibit enhanced binding to the cyclin B1 promoter, suggesting a role in cell cycle progression . Unlike phosphorylation at Thr-58, which promotes degradation, Ser-62 phosphorylation extends c-Myc's half-life, allowing sustained activation of target genes involved in proliferation and cellular transformation .

How does phosphorylation at Ser-62 regulate c-Myc stability compared to other post-translational modifications?

The stability of c-Myc is regulated through a complex interplay between different phosphorylation sites, particularly Ser-62 and Thr-58. Phosphorylation at Ser-62 significantly extends c-Myc's half-life by preventing its degradation through the ubiquitin-proteasome pathway. Research indicates that cyclin G1 overexpression leads to increased phosphorylation at Ser-62, which stabilizes the c-Myc protein . Interestingly, when examining point mutants, cells transfected with c-MycS62A (a phosphorylation-defective mutant) showed reduced protein expression, while c-MycT58A transfection maintained protein stability despite having a shortened half-life . This demonstrates the dominant role of Ser-62 phosphorylation in determining c-Myc stability compared to other modifications.

What kinases are responsible for phosphorylating c-Myc at Ser-62?

Cyclin-dependent kinase 5 (Cdk5) has been identified as a primary kinase responsible for c-Myc phosphorylation at Ser-62. Research demonstrates that Cdk5 activation in cells overexpressing cyclin G1 leads to increased phosphorylation of c-Myc at Ser-62 . In vitro studies confirm that Cdk5 directly binds to c-Myc, and this interaction is potentiated by cyclin G1 . When cells are treated with GST-cyclin G1 protein, c-Myc phosphorylation at Ser-62 increases via activation of Cdk5, and co-treatment with GST-Cdk5 dramatically enhances this phosphorylation . This pathway represents a significant regulatory mechanism for c-Myc activation and stability in various cellular contexts.

How specific are commercially available Phospho-c-Myc (Ser62) antibodies?

Commercial Phospho-c-Myc (Ser62) antibodies demonstrate high specificity for the phosphorylated form of c-Myc at Serine-62. According to product specifications, these antibodies detect endogenous levels of c-Myc protein only when phosphorylated at S62, without cross-reactivity to non-phosphorylated forms or other phosphorylation sites . Validation studies typically involve western blot analysis of cell lysates treated with phosphatase inhibitors versus controls. The specificity is further confirmed through the use of phosphorylation-defective mutants (c-MycS62A) as negative controls, where no signal should be detected . For optimal specificity validation, researchers should perform peptide competition assays using the phosphorylated and non-phosphorylated peptides around the Ser-62 site.

What are the critical factors for validating a new batch of Phospho-MYC (Ser62) antibody?

Validating a new batch of Phospho-MYC (Ser62) antibody requires multiple complementary approaches to ensure reliability. First, perform western blot analysis using positive controls (cells with known high levels of phosphorylated c-Myc) alongside negative controls (cells treated with phosphatase or expressing the S62A mutant) . Second, confirm specificity through peptide competition assays using both phosphorylated and non-phosphorylated peptides corresponding to the region around Ser-62. Third, validate the antibody across multiple applications (WB, IHC, IF) if intended for diverse experimental use . Fourth, perform chromatin immunoprecipitation (ChIP) assays to confirm that the antibody can detect the phosphorylated form bound to known c-Myc target genes like cyclin B1 promoter . Finally, compare results with previous batches to ensure consistent performance in your experimental system.

What are the optimal conditions for using Phospho-MYC (Ser62) antibodies in Western blot applications?

For optimal Western blot results with Phospho-MYC (Ser62) antibodies, sample preparation is critical. Cells should be lysed in buffers containing phosphatase inhibitors to preserve the phosphorylation status . The recommended dilution range for Western blot applications is typically 1:500-1:2000 for polyclonal antibodies and 1:500-1:1000 for monoclonal variants . When running SDS-PAGE, expect to visualize phospho-c-Myc at approximately 49 kDa . For optimal blocking, use 5% BSA in TBST rather than milk, as phospho-epitopes can be masked by phospho-proteins in milk. Incubate with primary antibody overnight at 4°C for best results. Secondary antibody selection should match the host species (typically rabbit) . Include appropriate controls: positive (cells treated with growth factors known to induce Ser-62 phosphorylation), negative (phosphatase-treated lysates), and specificity controls (competing phospho-peptides) to validate signal specificity.

How can Phospho-MYC (Ser62) antibodies be effectively used in chromatin immunoprecipitation (ChIP) assays?

For effective ChIP assays using Phospho-MYC (Ser62) antibodies, begin with proper crosslinking using 1% formaldehyde for 10 minutes at room temperature to preserve protein-DNA interactions. Based on experimental evidence, these antibodies can successfully immunoprecipitate phospho-c-Myc bound to target promoters like the cyclin B1 promoter containing E-box elements . For immunoprecipitation, use 2-5 μg of phospho-specific antibody per chromatin sample from approximately 1-2×10^6 cells. Include a non-specific IgG control and an antibody against total c-Myc for comparison. For detection, perform quantitative PCR using primers flanking known c-Myc binding sites, such as the E-box sequence (5'-CACGATG-3') . ChIP experiments have demonstrated that phospho-c-Myc (Ser-62), but not phospho-c-Myc (Thr-58), successfully binds to the cyclin B1 promoter, confirming the functional significance of this phosphorylation in transcriptional regulation .

What considerations are important when using Phospho-MYC (Ser62) antibodies for immunofluorescence studies?

When employing Phospho-MYC (Ser62) antibodies for immunofluorescence (IF), several technical considerations ensure optimal results. First, fixation method significantly impacts epitope preservation—4% paraformaldehyde for 15 minutes typically works well, but cold methanol fixation may better preserve phospho-epitopes in some cell types. The recommended dilution for IF applications ranges from 1:50-1:200 for monoclonal and 1:200-1:1000 for polyclonal antibodies . Include a permeabilization step with 0.1-0.5% Triton X-100 to allow antibody access to nuclear antigens, as phospho-c-Myc (Ser62) primarily localizes to the nucleus, nucleoplasm, and nucleolus . Blocking with 5% BSA in PBS is preferable to serum for phospho-specific antibodies. For signal verification, include controls with phosphatase treatment and competing phospho-peptides. Co-staining with antibodies against total c-Myc or nuclear markers helps contextualize the phospho-signal. Finally, due to potential weak signal, consider tyramide signal amplification if conventional detection methods yield insufficient results.

How can researchers distinguish between non-specific binding and true Phospho-MYC (Ser62) signal?

Distinguishing between non-specific binding and true Phospho-MYC (Ser62) signal requires multiple validation controls. First, include a dephosphorylation control—treat one sample with lambda phosphatase before immunoblotting to verify phospho-specificity; the signal should disappear in treated samples . Second, perform peptide competition assays using both phosphorylated and non-phosphorylated peptides spanning the Ser62 region; only the phospho-peptide should eliminate specific signal . Third, utilize phosphorylation-deficient mutants (c-MycS62A) as negative controls and compare them with wild-type or phospho-mimetic mutants . Fourth, compare staining patterns with total c-Myc antibodies—while patterns may not be identical due to differential localization of phosphorylated forms, they should overlap substantially in subcellular regions where c-Myc is active. Finally, verify results across multiple detection methods (e.g., if western blot and IF results contradict, further validation is needed).

What are common pitfalls in quantifying Phospho-MYC (Ser62) levels and how can they be avoided?

Quantifying Phospho-MYC (Ser62) levels presents several challenges requiring careful methodological approaches. A primary pitfall is failing to normalize phospho-signals correctly—always normalize to total c-Myc levels rather than housekeeping proteins, as changes in phosphorylation might not reflect changes in total protein expression . Another common issue is phosphatase activity during sample preparation; use fresh phosphatase inhibitor cocktails in all buffers and keep samples cold throughout processing . The timing of sample collection is also critical, as c-Myc phosphorylation is dynamic and cell cycle-dependent; synchronize cells when possible or document cell cycle status. Antibody saturation can give misleading results in highly expressing samples; perform dilution series to ensure linearity of detection. Finally, when comparing treatments or conditions, process all samples simultaneously with identical antibody concentrations and exposure times. For western blot quantification, use low-fluorescence membranes and fluorescent secondary antibodies rather than chemiluminescence for more accurate linear detection across a wider dynamic range.

How should researchers interpret discrepancies between Phospho-MYC (Ser62) levels and biological outcomes?

When faced with discrepancies between Phospho-MYC (Ser62) levels and expected biological outcomes, consider several explanatory factors. First, examine the interplay between multiple phosphorylation sites, as Ser62 phosphorylation works in concert with Thr58 and other modifications to determine c-Myc activity and stability . Second, consider context-dependent cofactors—c-Myc functions in complexes with proteins like MAX, and the availability of these partners may limit biological effects despite high phosphorylation levels . Third, assess target gene accessibility—epigenetic factors may restrict c-Myc access to certain promoters even when properly phosphorylated. Fourth, examine pathway crosstalk, as other signaling pathways may override or synergize with c-Myc activity in determining cellular outcomes. Finally, consider technical factors such as antibody cross-reactivity or post-lysis modifications that might affect detection accuracy . To resolve such discrepancies, complement phosphorylation analysis with functional assays like ChIP-seq to map actual binding events, reporter assays to measure transcriptional activity, and protein-protein interaction studies to identify relevant complexes in your specific biological context.

How can Phospho-MYC (Ser62) antibodies be used to study cancer-specific c-Myc activation?

Phospho-MYC (Ser62) antibodies offer powerful tools for investigating cancer-specific c-Myc activation mechanisms. Researchers can perform comparative immunohistochemistry on tissue microarrays containing matched tumor and normal tissue samples using dilutions between 1:100-1:300 to quantify differences in phosphorylation status . This approach has revealed elevated Ser62 phosphorylation in multiple cancer types, correlating with disease progression. For mechanistic studies, combined ChIP-seq using both phospho-specific and total c-Myc antibodies can identify cancer-specific target genes preferentially regulated by the Ser62-phosphorylated form . Phospho-MYC (Ser62) antibodies can also be employed in proximity ligation assays to visualize and quantify interactions between phosphorylated c-Myc and specific cofactors found in cancer cells. Additionally, these antibodies serve as valuable pharmacodynamic markers in preclinical studies of therapeutics targeting Cdk5 or other kinases involved in c-Myc regulation, helping to establish target engagement and pathway modulation before observable phenotypic changes .

What are the latest methodological advances in studying Phospho-MYC (Ser62) dynamics in live cells?

Recent methodological advances have significantly enhanced the study of Phospho-MYC (Ser62) dynamics in live cells. Though conventional phospho-specific antibodies cannot penetrate live cells, researchers now employ genetically encoded biosensors based on fluorescence resonance energy transfer (FRET) technology. These biosensors incorporate c-Myc fragments containing the Ser62 region positioned between fluorescent protein pairs, allowing real-time visualization of phosphorylation events. Another innovative approach involves using cell-permeable nanobodies derived from Phospho-MYC (Ser62) antibodies conjugated to fluorescent labels, enabling live-cell imaging of endogenous phosphorylated c-Myc. Mass spectrometry-based approaches like selected reaction monitoring (SRM) now provide absolute quantification of Ser62 phosphorylation stoichiometry in complex samples. Additionally, CRISPR-Cas9 gene editing to introduce specific mutations (S62A or phosphomimetic S62D/E) tagged with fluorescent proteins allows comparative studies of phosphorylation effects on c-Myc localization and dynamics. These techniques complement traditional antibody-based approaches and offer unprecedented insights into the spatiotemporal regulation of c-Myc phosphorylation in various physiological and pathological contexts.

How does Phospho-MYC (Ser62) interact with other post-translational modifications to form the "c-Myc code"?

Phospho-MYC (Ser62) functions within a complex network of post-translational modifications (PTMs) that collectively form a regulatory "c-Myc code." Research shows that Ser62 phosphorylation has a hierarchical relationship with Thr58 phosphorylation—Ser62 phosphorylation must occur first and actually primes c-Myc for subsequent Thr58 phosphorylation by GSK-3β . While Ser62 phosphorylation stabilizes c-Myc, Thr58 phosphorylation promotes its degradation, creating a temporal activity window. This PTM interplay can be studied using combinations of phospho-specific antibodies in sequential immunoprecipitation experiments . Beyond phosphorylation, Ser62-phosphorylated c-Myc shows differential interactions with acetylation at specific lysine residues, which can be analyzed using antibodies against both modifications. Ubiquitination patterns also differ between Ser62-phosphorylated and non-phosphorylated c-Myc, with the former showing resistance to certain E3 ligases. Mass spectrometry approaches have revealed that Ser62 phosphorylation influences sumoylation and methylation at distant residues, suggesting allosteric effects on protein structure. Understanding these combinatorial modifications is critical for deciphering the complete regulatory mechanisms controlling c-Myc function in different cellular contexts and developing targeted therapeutic approaches.

What control experiments are essential when studying Phospho-MYC (Ser62) in different cell types?

When studying Phospho-MYC (Ser62) across different cell types, essential control experiments ensure reliable data interpretation. First, validate antibody specificity in each cell type by comparing detection in wild-type cells versus those expressing phospho-deficient S62A mutants . Second, establish baseline phosphorylation levels in growth factor-starved conditions followed by stimulation with serum or specific growth factors to confirm the antibody detects dynamic changes. Third, perform time-course experiments with Cdk5 inhibitors or siRNA to demonstrate specificity of the kinase-substrate relationship in your cell system . Fourth, include tissue/cell-type-specific positive controls (e.g., certain cancer cell lines with known high Ser62 phosphorylation) and negative controls (normal counterparts or differentiated cells with lower c-Myc activity). Fifth, when comparing phosphorylation between cell types, normalize not just to total c-Myc but consider differences in cell cycle distribution, as c-Myc phosphorylation varies throughout the cell cycle. Finally, confirm functional relevance by correlating phosphorylation levels with downstream effects such as binding to target promoters using ChIP assays with primers specific for known c-Myc targets like cyclin B1 .

How should researchers design experiments to study the temporal dynamics of c-Myc Ser62 phosphorylation?

Designing experiments to capture the temporal dynamics of c-Myc Ser62 phosphorylation requires careful planning and multiple complementary approaches. Begin with synchronization of cells using serum starvation followed by release, collecting samples at close intervals (15-30 minutes) for the first 2-3 hours, then at hourly intervals thereafter. For western blot analysis, use standardized lysate amounts and include both phospho-Ser62 and total c-Myc antibodies on replicate blots or with sequential probing after thorough stripping . Employ flow cytometry with fluorescently labeled Phospho-MYC (Ser62) antibodies combined with DNA content staining to correlate phosphorylation status with cell cycle position at the single-cell level. For high-temporal resolution, live-cell imaging with FRET-based reporters containing the Ser62 region provides continuous monitoring capability. Complement these approaches with ChIP assays at key timepoints to determine how phosphorylation correlates with genomic binding dynamics . Finally, implement phospho-proteomic mass spectrometry for absolute quantification of phosphorylation stoichiometry across the time course. This multi-method approach provides comprehensive understanding of both the timing and functional consequences of Ser62 phosphorylation in your experimental system.

How does altered Phospho-MYC (Ser62) signaling contribute to specific cancer phenotypes?

Altered Phospho-MYC (Ser62) signaling contributes to cancer phenotypes through multiple mechanisms with context-dependent outcomes. Enhanced Ser62 phosphorylation stabilizes c-Myc protein, leading to sustained expression of growth-promoting target genes and increased cellular proliferation . This modification increases c-Myc's DNA binding activity, particularly to E-box elements in promoters of cell cycle regulators like cyclin B1, as demonstrated by ChIP assays . The heightened transcriptional activity driven by Ser62 phosphorylation promotes metabolic reprogramming through upregulation of glycolytic enzymes and glutamine metabolism genes, supporting the increased energy demands of cancer cells. Research using phospho-specific antibodies has revealed that dysregulation of upstream kinases like Cdk5, which directly phosphorylates c-Myc at Ser62, contributes to aberrant activation in multiple tumor types . Furthermore, impaired phosphatase activity or disruption of the phosphorylation-dephosphorylation cycle can lead to accumulation of Ser62-phosphorylated c-Myc. Importantly, this modification appears to alter c-Myc's partner preference and target selectivity, potentially explaining why c-Myc overexpression yields different phenotypes across cancer types.

What methodological approaches best capture the relationship between Phospho-MYC (Ser62) levels and therapeutic responses?

To effectively capture the relationship between Phospho-MYC (Ser62) levels and therapeutic responses, researchers should implement a multi-faceted methodological approach. Begin with baseline assessment of Ser62 phosphorylation status in patient-derived samples or model systems using validated antibodies at appropriate dilutions (1:100-1:300 for IHC; 1:500-1:2000 for WB) . Monitor changes during treatment using serial biopsies or liquid biopsy approaches where circulating tumor cells or extracellular vesicles are analyzed for phospho-c-Myc content. Develop pharmacodynamic assays where phospho-c-Myc serves as a biomarker for target engagement, particularly for therapies targeting upstream kinases like Cdk5 . Combine direct measurement of phosphorylation with functional readouts such as ChIP-seq to assess genome-wide binding changes and RNA-seq to quantify alterations in target gene expression profiles. For high-throughput screening, establish cell-based reporter systems where Ser62 phosphorylation status is linked to easily measurable outputs. Finally, implement multiplex immunofluorescence approaches to simultaneously assess phospho-c-Myc levels alongside markers of proliferation, apoptosis, and other relevant pathways in clinical samples, enabling correlation analyses between phosphorylation patterns and treatment outcomes across heterogeneous tumor regions.

What sample preparation techniques best preserve Phospho-MYC (Ser62) for different analytical methods?

Optimal preservation of Phospho-MYC (Ser62) requires tailored sample preparation techniques for different analytical methods. For Western blot analysis, rapid sample processing is crucial—lyse cells directly in ice-cold RIPA or NP-40 buffer supplemented with fresh phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and β-glycerophosphate) . For tissue samples, snap-freezing in liquid nitrogen followed by homogenization in phosphatase inhibitor-containing buffers maximizes phospho-epitope preservation. When preparing samples for immunohistochemistry or immunofluorescence, use phosphate-buffered 4% paraformaldehyde fixation for 15-20 minutes rather than longer protocols, as extended fixation can mask phospho-epitopes . For tissues requiring paraffin embedding, implement phospho-epitope preservation protocols with brief fixation followed by rapid processing. During antigen retrieval, citrate buffer (pH 6.0) typically works better than EDTA-based buffers for phospho-c-Myc epitopes. For immunoprecipitation applications, use non-denaturing lysis buffers with phosphatase inhibitors and keep samples at 4°C throughout processing . For mass spectrometry analysis, immediate denaturation in 8M urea with phosphatase inhibitors, followed by reduction, alkylation, and digestion with sequence-specific proteases (rather than trypsin alone) improves phosphopeptide recovery around the Ser62 region.

How can researchers optimize signal detection for low abundance Phospho-MYC (Ser62) in challenging samples?

Optimizing detection of low abundance Phospho-MYC (Ser62) in challenging samples requires both technical refinements and signal amplification strategies. For Western blot applications, implement protein concentration steps using immunoprecipitation with total c-Myc antibodies before probing with phospho-specific antibodies at 1:500 dilution . Consider using high-sensitivity chemiluminescent substrates with extended exposure times on cooled CCD cameras rather than film for better low-signal detection. For immunohistochemistry in tissues with low expression, employ polymer-based detection systems or tyramide signal amplification, which can enhance sensitivity 10-50 fold compared to conventional methods . When using immunofluorescence, implement sequential signal amplification with species-specific secondary antibodies followed by tertiary detection. Consider sample enrichment techniques such as phosphoprotein isolation using commercial kits before analysis. For mass spectrometry approaches, implement phosphopeptide enrichment using titanium dioxide (TiO₂) or immobilized metal affinity chromatography (IMAC) methods optimized for Ser-phosphorylated peptides. Regardless of method, always process experimental and control samples identically to ensure that enhanced sensitivity does not come at the expense of specificity, confirming signals with appropriate negative controls .

How might single-cell analysis of Phospho-MYC (Ser62) advance our understanding of cellular heterogeneity in cancer?

Single-cell analysis of Phospho-MYC (Ser62) offers unprecedented insights into tumor heterogeneity and cellular subpopulations with distinct c-Myc activation states. Unlike bulk tissue analysis that averages signals across populations, single-cell approaches reveal distinct subsets of cells with varying phosphorylation levels, which may represent different functional states or drug-responsive populations. Methodologically, mass cytometry (CyTOF) with metal-conjugated Phospho-MYC (Ser62) antibodies enables simultaneous quantification of multiple signaling pathways alongside phospho-c-Myc in thousands of individual cells . Single-cell Western blot technologies allow protein-level confirmation of phosphorylation status in select cells identified by microscopy. Additionally, spatial profiling techniques like multiplexed ion beam imaging (MIBI) or co-detection by indexing (CODEX) can map phospho-c-Myc distribution within the tumor microenvironment, revealing potential niches with elevated signaling. These approaches can identify rare cell populations with unique phosphorylation patterns that might drive tumor progression or resistance but would be missed in bulk analyses. By correlating single-cell phospho-c-Myc profiles with transcriptional states (through parallel single-cell RNA-seq) and phenotypic behaviors, researchers can develop more precise models of how heterogeneous c-Myc activation contributes to cancer biology and therapeutic response.